₹570 Crore Draft Assessment Puts Audit Committee Risk Evaluation Under Scrutiny

Divi’s Laboratories received a draft assessment order from the Income Tax Department proposing additions of ₹570 crore for FY23, stemming from transfer pricing adjustments on specified domestic transactions and corporate tax adjustments. The pharmaceutical major disclosed this development to the exchanges, noting that these are proposed adjustments in a draft order.

The timing coincides with the company’s ongoing earnings season disclosures, where tax provisions and contingent liabilities receive heightened scrutiny from institutional investors. Transfer pricing disputes in the pharmaceutical sector have become increasingly common as the I-T Department focuses on inter-company transactions, particularly those involving intellectual property and manufacturing arrangements.

What stands out in this disclosure is the scale of the proposed adjustment relative to the company’s tax planning framework. The ₹570 crore figure represents a substantial addition that would materially impact the company’s effective tax rate calculations and require detailed evaluation by the audit committee regarding adequacy of existing tax provisions.

The company’s response indicates it will file appropriate replies and representations during the assessment proceedings. This standard language masks the complexity of defending transfer pricing positions, especially when domestic transactions are involved. The I-T Department’s focus on ‘specified domestic transactions’ suggests scrutiny of arrangements between related entities within India, which often involve cost-sharing agreements or profit margin allocations.

Pharmaceutical companies face particular transfer pricing challenges due to the nature of their value chains. Research and development costs, manufacturing processes, and distribution arrangements across group entities create multiple touchpoints for regulatory examination. The Department’s approach to these transactions has evolved significantly, with greater emphasis on substance over form in recent assessments.

The disclosure framework requires companies to evaluate whether such tax disputes constitute contingent liabilities requiring specific provision or disclosure treatment. Audit committees must assess management’s position on the merits of the case, the adequacy of legal and tax advisory support, and the potential financial impact on reported earnings.

For Divi’s Laboratories, this development adds a layer of complexity to investor communications during results season. The company will need to address questions about its transfer pricing policies, the basis for the Department’s objections, and the timeline for resolution. These conversations typically involve detailed discussions about the company’s interpretation of arm’s length pricing principles and documentation supporting inter-company transactions.

The pharmaceutical sector has seen similar cases where initial draft assessments undergo substantial revision during the appellate process. However, the time and resources required for such proceedings can extend over multiple financial years, creating ongoing disclosure obligations and investor uncertainty.

Corporate tax adjustments mentioned alongside transfer pricing issues suggest the Department may have raised questions beyond inter-company pricing. These could involve deductions claimed, depreciation methods, or timing differences in revenue recognition. The combination of both categories indicates a comprehensive review of the company’s tax positions for FY23.

My Boardroom Takeaway: Audit committees should examine whether existing tax risk frameworks adequately capture the evolving regulatory approach to transfer pricing, particularly for domestic transactions. Directors may wish to review the frequency and depth of transfer pricing documentation updates, especially given the Department’s increased focus on pharmaceutical sector arrangements. The committee should also assess whether current tax provisioning methodologies reflect the potential for such significant adjustments, as ₹570 crore additions could materially impact financial statement accuracy and investor expectations.